BG Medicine (OTCMKTS:BGMD) versus PACS Group (NYSE:PACS) Head-To-Head Survey

PACS Group (NYSE:PACS) and BG Medicine (OTCMKTS:BGMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for PACS Group and BG Medicine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0	1	4	1	3.00
BG Medicine	0	0	0	0	0.00

PACS Group currently has a consensus target price of $44.40, indicating a potential upside of 32.97%. Given PACS Group’s stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than BG Medicine.

Volatility and Risk

PACS Group has a beta of -0.63, meaning that its stock price is 163% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Profitability

This table compares PACS Group and BG Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PACS Group	3.62%	22.55%	3.45%
BG Medicine	N/A	N/A	N/A

Valuation and Earnings

This table compares PACS Group and BG Medicine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29 billion	0.99	$191.54 million	$1.23	27.15
BG Medicine	N/A	N/A	N/A	N/A	N/A

PACS Group has higher revenue and earnings than BG Medicine.

Summary

PACS Group beats BG Medicine on 8 of the 9 factors compared between the two stocks.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.